375
Participants
Start Date
April 9, 2013
Primary Completion Date
July 31, 2017
Study Completion Date
October 31, 2017
SPARC1104 modified dose regimen I
Subjects who exited study CLR\_09\_21
SPARC1104 modified dose regimen II
Subjects who received prior treatment regimen I
SPARC1104 modified dose regimen III
Subjects who received no prior treatment regimen
SPARC Site 52, White Plains
SPARC Site 43, Rochester
SPARC Site 57, Abington
SPARC Site 50, Washington D.C.
SPARC Site 22, Fulton
SPARC Site 62, Huntington
SPARC Site 2, Winston-Salem
SPARC Site 18, Greensboro
SPARC site 39, Charlotte
SPARC Site 23, Old Point Station
SPARC Site 6, Ormond Beach
SPARC Site 35, Maitland
SPARC Site 59, Miami
SPARC Site 25, Sunrise
SPARC Site 55, Tampa
SPARC Site 33, Tampa
SPARC Site 11, Port Charlotte
SPARC Site 13, Sarasota
SPARC Site 44, Louisville
SPARC Site 27, Centerville
SPARC Site 26, Clinton Township
SPARC Site 54, Detroit
SPARC Site 56, Waukesha
SPARC Site 58, Milwaukee
SPARC Site 19, Golden Valley
SPARC Site 24, Overland Park
SPARC site 45, Lenexa
SPARC Site 61, New Orleans
SPARC Site 21, Baton Rouge
SPARC site 36, Alexandria
SPARC Site 60, Dallas
SPARC Site 37, Houston
SPARC Site 5, Austin
SPARC Site 5, Denver
SPARC Site 32, Basalt
SPARC Site 34, Phoenix
SPARC site 4, Gilbert
SPARC Site 1, Tucson
SPARC Site 16, Albuquerque
SPARC Site 30, Costa Mesa
SPARC Site 14, Newport Beach
SPARC site 10, Eugene
SPARC site 38, Springfield
SPARC Site 20, Tacoma
SPARC Site 49, Baltimore
SPARC Site 29, Foxborough
SPARC Site 17, Springfield
SPARC Site 28, Flemington
SPARC Site 7, Derby
SPARC site 47, Hartford
SPARC Site 8, New London
Sun Pharma Advanced Research Company Limited
INDUSTRY